VKTX

In the past six months, Viking Therapeutics' stock price has been significantly impacted by positive clinical trial results and financing activities. On September 22, 2026, the stock surged following positive top-line results from its VK2735 maintenance study, which showed significant placebo-adjusted weight loss and high weight loss retention with a favorable safety profile, causing a 24-36% stock jump. During the fiscal Q2 2026 earnings report on July 29, 2026, the company confirmed full enrollment in Phase 3 VANQUISH-1 and VANQUISH-2 trials for subcutaneous VK2735 and announced plans to initiate Phase 3 trials for the oral formulation in fiscal Q4 2026. On September 23, 2026, Viking Therapeutics announced proposed offerings of common stock and convertible senior notes. In March 2026, the company partnered with CordenPharma for VK2735 development and commercialization, and in June 2026, it signed an equity distribution agreement with Maxim Group. The stock has seen a 66.50% increase over the last 12 months, with an 18.18% year-to-date return and a 22.67% increase in the past month.